BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 36088370)

  • 21. DNA vaccine elicits an efficient antitumor response by targeting the mutant Kras in a transgenic mouse lung cancer model.
    Weng TY; Yen MC; Huang CT; Hung JJ; Chen YL; Chen WC; Wang CY; Chang JY; Lai MD
    Gene Ther; 2014 Oct; 21(10):888-96. PubMed ID: 25077772
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Loss of p53 attenuates the contribution of IL-6 deletion on suppressed tumor progression and extended survival in Kras-driven murine lung cancer.
    Tan X; Carretero J; Chen Z; Zhang J; Wang Y; Chen J; Li X; Ye H; Tang C; Cheng X; Hou N; Yang X; Wong KK
    PLoS One; 2013; 8(11):e80885. PubMed ID: 24260500
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of novel peptide inhibitors for oncogenic KRAS G12D as therapeutic options using mutagenesis-based remodeling and MD simulations.
    Samad A; Khurshid B; Mahmood A; Rehman AU; Khalid A; Abdalla AN; Algarni AS; Wadood A
    J Biomol Struct Dyn; 2023; 41(22):13425-13437. PubMed ID: 37010994
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS
    Wang X; Allen S; Blake JF; Bowcut V; Briere DM; Calinisan A; Dahlke JR; Fell JB; Fischer JP; Gunn RJ; Hallin J; Laguer J; Lawson JD; Medwid J; Newhouse B; Nguyen P; O'Leary JM; Olson P; Pajk S; Rahbaek L; Rodriguez M; Smith CR; Tang TP; Thomas NC; Vanderpool D; Vigers GP; Christensen JG; Marx MA
    J Med Chem; 2022 Feb; 65(4):3123-3133. PubMed ID: 34889605
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of New KRAS G12D Inhibitors through Computer-Aided Drug Discovery Methods.
    Kulkarni AM; Kumar V; Parate S; Lee G; Yoon S; Lee KW
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163234
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovering and Targeting Dynamic Drugging Pockets of Oncogenic Proteins: The Role of Magnesium in Conformational Changes of the G12D Mutated Kirsten Rat Sarcoma-Guanosine Diphosphate Complex.
    Hu Z; Marti J
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430338
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Facts and Hopes in Immunotherapy Strategies Targeting Antigens Derived from KRAS Mutations.
    Linette GP; Bear AS; Carreno BM
    Clin Cancer Res; 2024 May; 30(10):2017-2024. PubMed ID: 38266167
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of T Cell Receptors Targeting a Neoantigen Derived from Recurrently Mutated FGFR3.
    Tate T; Matsumoto S; Nemoto K; Leisegang M; Nagayama S; Obama K; Nakamura Y; Kiyotani K
    Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831375
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mouse model of proximal colon-specific tumorigenesis driven by microsatellite instability-induced Cre-mediated inactivation of Apc and activation of Kras.
    Kawaguchi Y; Hinoi T; Saito Y; Adachi T; Miguchi M; Niitsu H; Sasada T; Shimomura M; Egi H; Oka S; Tanaka S; Chayama K; Sentani K; Oue N; Yasui W; Ohdan H
    J Gastroenterol; 2016 May; 51(5):447-57. PubMed ID: 26361962
    [TBL] [Abstract][Full Text] [Related]  

  • 30. T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer.
    Tran E; Robbins PF; Lu YC; Prickett TD; Gartner JJ; Jia L; Pasetto A; Zheng Z; Ray S; Groh EM; Kriley IR; Rosenberg SA
    N Engl J Med; 2016 Dec; 375(23):2255-2262. PubMed ID: 27959684
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interleukin-17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 Blockade.
    Akbay EA; Koyama S; Liu Y; Dries R; Bufe LE; Silkes M; Alam MM; Magee DM; Jones R; Jinushi M; Kulkarni M; Carretero J; Wang X; Warner-Hatten T; Cavanaugh JD; Osa A; Kumanogoh A; Freeman GJ; Awad MM; Christiani DC; Bueno R; Hammerman PS; Dranoff G; Wong KK
    J Thorac Oncol; 2017 Aug; 12(8):1268-1279. PubMed ID: 28483607
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition mechanism of MRTX1133 on KRAS
    Liang F; Kang Z; Sun X; Chen J; Duan X; He H; Cheng J
    J Comput Aided Mol Des; 2023 Mar; 37(3):157-166. PubMed ID: 36849761
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes.
    Aredo JV; Padda SK; Kunder CA; Han SS; Neal JW; Shrager JB; Wakelee HA
    Lung Cancer; 2019 Jul; 133():144-150. PubMed ID: 31200821
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synergistic signaling of KRAS and thyroid hormone receptor β mutants promotes undifferentiated thyroid cancer through MYC up-regulation.
    Zhu X; Zhao L; Park JW; Willingham MC; Cheng SY
    Neoplasia; 2014 Sep; 16(9):757-69. PubMed ID: 25246276
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ADAM17 selectively activates the IL-6 trans-signaling/ERK MAPK axis in KRAS-addicted lung cancer.
    Saad MI; Alhayyani S; McLeod L; Yu L; Alanazi M; Deswaerte V; Tang K; Jarde T; Smith JA; Prodanovic Z; Tate MD; Balic JJ; Watkins DN; Cain JE; Bozinovski S; Algar E; Kohmoto T; Ebi H; Ferlin W; Garbers C; Ruwanpura S; Sagi I; Rose-John S; Jenkins BJ
    EMBO Mol Med; 2019 Apr; 11(4):. PubMed ID: 30833304
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Highly Potent, Selective, Biostable, and Cell-Permeable Cyclic d-Peptide for Dual-Targeting Therapy of Lung Cancer.
    Zhou Y; Zou Y; Yang M; Mei S; Liu X; Han H; Zhang CD; Niu MM
    J Am Chem Soc; 2022 Apr; 144(16):7117-7128. PubMed ID: 35417174
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting intracellular oncoproteins with dimeric IgA promotes expulsion from the cytoplasm and immune-mediated control of epithelial cancers.
    Biswas S; Mandal G; Anadon CM; Chaurio RA; Lopez-Bailon LU; Nagy MZ; Mine JA; Hänggi K; Sprenger KB; Innamarato P; Harro CM; Powers JJ; Johnson J; Fang B; Eysha M; Nan X; Li R; Perez BA; Curiel TJ; Yu X; Rodriguez PC; Conejo-Garcia JR
    Immunity; 2023 Nov; 56(11):2570-2583.e6. PubMed ID: 37909039
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mutation-Specific and Common Phosphotyrosine Signatures of
    Tahir R; Renuse S; Udainiya S; Madugundu AK; Cutler JA; Nirujogi RS; Na CH; Xu Y; Wu X; Pandey A
    J Proteome Res; 2021 Jan; 20(1):670-683. PubMed ID: 32986951
    [No Abstract]   [Full Text] [Related]  

  • 39. Isolation of T cell receptors targeting recurrent neoantigens in hematological malignancies.
    Tubb VM; Schrikkema DS; Croft NP; Purcell AW; Linnemann C; Freriks MR; Chen F; Long HM; Lee SP; Bendle GM
    J Immunother Cancer; 2018 Jul; 6(1):70. PubMed ID: 30001747
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined Mutation of
    Sakai E; Nakayama M; Oshima H; Kouyama Y; Niida A; Fujii S; Ochiai A; Nakayama KI; Mimori K; Suzuki Y; Hong CP; Ock CY; Kim SJ; Oshima M
    Cancer Res; 2018 Mar; 78(5):1334-1346. PubMed ID: 29282223
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.